CellaVision concludes acquisition of RAL Diagnostics.

NORDIC BUSINESS REPORT-October 3, 2019-CellaVision concludes acquisition of RAL Diagnostics

(C)2019 M2 COMMUNICATIONS http://www.m2.com

Medical technology company CellaVision AB (STO:CEVI) announced on Wednesday that it has completed its acquisition of RAL Diagnostics, a company focused on the production and sale of products for sample preparation in haematology, pathology, cytology and microbiology.

Financial details of the acquisition were not available.

According to CellaVision, RAL Diagnostics complements its own products very well in haematology and this acquisition is strategically important in both the short and long term. RAL Diagnostics, located in...

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT